Minireviews
Copyright ©The Author(s) 2018.
World J Gastrointest Oncol. Sep 15, 2018; 10(9): 271-281
Published online Sep 15, 2018. doi: 10.4251/wjgo.v10.i9.271
Table 1 The main randomized trials in gastric cancer that evaluate the postoperative therapy
TrialYearRandomization schemeOSDFS, PFSLimits
SWOG/INT-0116[6]2001S-alone vs S + CRT3-yr: 50% vs 41% (P = 0.005)3-yr: 48% vs 31% (P < 0.001)Low rates of D2 node dissection, 2D RT technique
Update SWOG/INT-0116[7]2012S-alone vs S + CRTHR = 1.32 (95%CI: 1.10-1.60; P = 0.0046)HR = 1.51 (95%CI: 1.25-1.83; P < 0.001)Low rates of D2 node dissection, 2D RT technique
ARTIST[11] CRITICS[16]2012 2018S + CT + CRT + CT vs S + CT CT + S + CT vs CT + S + CRTNR Median OS 43 vs 37 mo (P = 0.09)3-yr: 78% vs 74% (P = 0.086)Planned events not reached, lower % of locally advanced tumors Poor postoperative patient compliance in both treatment arms
NCC, South Korea[17]2012S + CRT vs S + CTNR5-yr: 73.5% vs 54.6%, (P = 0.056)Poor accrual Sometimes 2D RT technique
Chinese Study[18]2012S + CRT vs S + CT5-yr: 48.4% vs 41.8% (P = 0.122)5-yr: 45.2% vs 35.8% (P = NS)Small series
ACTS-GC[19]2007S-alone vs S + CT3-yr: 80.1% vs 70.1% (P = 0.003)3-yr: 59.6% vs 72.2% (P < 0.001)Closed earlier due to significant survival benefit in the CT-arm
CLASSIC[20]2012S-alone vs S + CTNR3-yr: 59% vs 74% (P < 0.0001)Stopped after the interim efficacy analysis